Abstract
AbstractThe pursuit of effective treatments for metastatic cancer is still one of the most intensive areas of research in the biomedical field. In a not‐so‐distant past, the scientific community has witnessed the rise of immunotherapy based on immune checkpoint inhibitors (ICIs). This therapeutic modality intends to abolish immunosuppressive interactions, re‐establishing T cell responses against metastasized cancer cells. Despite the initial enthusiasm, the ICIs were later found to be associated with low clinical therapeutic outcomes and immune‐related side effects. To address these limitations, researchers are exploring the combination of ICIs with nanomaterial‐mediated phototherapies. These nanomaterials can accumulate within the tumor and produce, upon interaction with light, a temperature increase (photothermal therapy) and/or reactive oxygen species (photodynamic therapy), causing damage to cancer cells. Importantly, these photothermal‐photodynamic effects can pave the way for an enhanced ICI‐based immunotherapy by inducing the release of tumor‐associated antigens and danger‐associated molecular patterns, as well as by relieving tumor hypoxia and triggering a pro‐inflammatory response. This progress report analyses the potential of nanomaterial‐mediated photothermal‐photodynamic therapy in combination with ICIs, focusing on their ability to modulate T cell populations leading to an anti‐metastatic abscopal effect and on their capacity to generate immune memory that prevents tumor recurrence.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.